REVIEW OF THE ONCOLOGICAL UROLOGY PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2018 ANNUAL MEETING
https://doi.org/10.17650/1726-9776-2018-14-3-143-148
Abstract
The 54th American Society of Clinical Oncology (ASCO) Annual Meeting took place between 1st and 5th June in Chicago (USA) united more than 40,700 professionals of various fields. Oncological urology topics account for a considerable proportion of the Annual Meeting proceedings. In this article, a review of the most significant reports on cancer urology from the ASCO 2018 Annual Meeting is presented.
About the Authors
A. A. Kirichek
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
Competing Interests:
No conflict of interest.
B. Sh. Kamolov
European Medical Center
Russian Federation
35 Shchepkina St., Moscow 129090.
Competing Interests:
Russian Federation
35 Shchepkina St., Moscow 129090.
Competing Interests:
No conflict of interest.
V. B. Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
24 Kashirskoe Shosse, Moscow 115478.
Competing Interests:
No conflict of interest.
B. M. Nazranov
City Clinical Hospital No. 1
Russian Federation
Competing Interests:
Russian Federation
7 Golovko St., Nalchik 360004, Kabardino-Balkar Republic.
Competing Interests:
No conflict of interest.
References
1. Castello A., Macapinlac H.A., Lopci E. et al. Prostate-specific antigen flare in-duced by 223RaCl2 in patients with meta-static castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018 May 21 (in press). DOI: 10.1007/s00259-018-4051-y. PMID: 29785515.
2. Clarke N., Wiechno P., Alekseev B. et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2018;19(7):975–86. DOI: 10.1016/S1470-2045(18)30365-6. PMID: 29880291.
3. Hansen A.R., Massard C., Ott P.A. et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 2018;29(8):1807–13. DOI: 10.1093/annonc/mdy232. PMID: 29992241.
4. McNeel D.G., Eickhoff J.C., Wargowski E. et al. Concurrent, but not sequential, PD-blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget 2018;9(39):25586–96. DOI: 10.18632/oncotarget.25387. PMID: 29876010.
5. McDermott D., Lee Ja.L., Szczylik C. et al. Pembrolizumab monotherapy as firstline therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. J Clin Oncol 2018;S15:4500. DOI: 10.1200/JCO.2018.36.15_suppl.4500.
6. McDermott D., Huseni M.A., Atkins M.B. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018;24(6):749–57. DOI: 10.1038/s41591-018-0053-3. PMID: 29867230.
7. Powles T., Duran I., van der Heijden M.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391(10122):748–57. DOI: 10.1016/S0140-6736(17)33297-X. PMID: 29268948.
8. Li Q., Baqrodia A., Cha E.K. et al. Prognostic genetic signatures in upper tract urothelial carcinoma. Curr Urol Rep 2016;17(2):12. DOI: 10.1007/s11934-015-0566-y.
9. Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI: 10.1056/NEJMoa1613683. PMID: 28212060.
Review
For citations:
Kirichek A.A., Kamolov B.Sh., Matveev V.B., Nazranov B.M. REVIEW OF THE ONCOLOGICAL UROLOGY PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2018 ANNUAL MEETING. Cancer Urology. 2018;14(3):143-148. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-3-143-148
Views:
920
Email this article 